Kymera Therapeutics Revenue and Competitors

Boston, MA USA

Location

$454M

Total Funding

Biotech

Industry

Estimated Revenue & Valuation

  • Kymera Therapeutics's estimated annual revenue is currently $25.6M per year.(i)
  • Kymera Therapeutics's estimated revenue per employee is $125,985
  • Kymera Therapeutics's total funding is $454M.

Employee Data

  • Kymera Therapeutics has 203 Employees.(i)
  • Kymera Therapeutics grew their employee count by 27% last year.

Kymera Therapeutics's People

NameTitleEmail/Phone
1
Founder, President and CEOReveal Email/Phone
2
Chief Financial OfficerReveal Email/Phone
3
VPReveal Email/Phone
4
Head Strategic SourcingReveal Email/Phone
5
SVP, Information Technology and OperationsReveal Email/Phone
6
VP FinanceReveal Email/Phone
7
VP Preclinical DevelopmentReveal Email/Phone
8
VP, People + CultureReveal Email/Phone
9
VP, Head Business DevelopmentReveal Email/Phone
10
SVP, Head ResearchReveal Email/Phone
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingValuation
#1
$5.2M67-45%$107.3MN/A
#2
$0.3M20%N/AN/A
#3
$5.1M336%N/AN/A
#4
$11.9M77-37%$312.8MN/A
#5
$0.9M60%N/AN/A
#6
$235M300-5%$340.9MN/A
#7
$45.9M237-7%$7.6MN/A
#8
$3.9M5035%N/AN/A
#9
$5.4M353%N/AN/A
#10
$1.6M100%N/AN/A
Add Company

What Is Kymera Therapeutics?

Kymera Therapeutics is pioneering a transformative new approach to treating previously untreatable diseases. We are advancing the field of targeted protein degradation, accessing the body's innate protein recycling machinery to degrade rather than inhibit dysregulated, disease-causing proteins. Powered by a proprietary predictive modeling capability and a game-changing integrated degradation platform with a novel small molecule modality, our company is committed to accelerating drug discovery with an unmatched ability to target and degrade the most intractable of proteins, and advance new treatment options for patients. Learn more at kymeratx.com.

keywords:N/A

$454M

Total Funding

203

Number of Employees

$25.6M

Revenue (est)

27%

Employee Growth %

N/A

Valuation

N/A

Accelerator

Kymera Therapeutics News

2022-04-17 - Zacks: Analysts Expect Kymera Therapeutics, Inc. (NASDAQ ...

Kymera Therapeutics, Inc, a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics that selectively...

2022-04-17 - Shareholders in Kymera Therapeutics (NASDAQ:KYMR) have lost 11%, as stock drops 8.8% this past week

Shareholders in Kymera Therapeutics (NASDAQ:KYMR) have lost 11%, as stock drops 8.8% this past week. By: Simply Wall St. Published: April 22,...

2022-04-06 - Kymera Therapeutics Presents Preclinical Data Highlighting ...

WATERTOWN, Mass., April 08, 2022 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company...

2020-03-12 - Kymera Therapeutics Announces $102 Million Series C Financing

Kymera Therapeutics Inc., a biotechnology company pioneering targeted protein degradation to invent breakthrough protein degrader medicines for patients, today announced the closing of a $102 million Series C financing. The round was led by Biotechnology Value Fund (BVF) and Redmile Group with p ...

2020-03-12 - Kymera Therapeutics Raises $102M in Series C Financing

Kymera Therapeutics Inc., a Cambridge, Mass.-based biotechnology company pioneering targeted protein degradation to invent breakthrough protein degrader medicines for patients, closed a $102m Series C financing. The round was led by Biotechnology Value Fund (BVF) and Redmile Group with particip ...

Company NameRevenueNumber of EmployeesEmployee GrowthTotal Funding
#1
$51M2035%N/A
#2
$31.6M2046%N/A
#3
$49.6M20510%N/A
#4
$32M205-13%$3.2M
#5
$31.3M208-34%$1.9B